Skip to content

Evolent Health, Inc. EVH Cash & Equivalents

Cash & Equivalents at other companies

CVS Health logo
CVS HealthCVS
$9.77B-5.6%
UnitedHealth Group logo
UnitedHealth GroupUNH
$28B-8.8%
The Oncology Institute, Inc. logo
The Oncology Institute, Inc.TOI
$30.28M-23.8%
Astrana Health logo
Astrana HealthASTH
$478.38M+85.0%
BrightSpring Health Services, Inc. logo
BrightSpring Health Services, Inc.BTSG
$888.8M+1,598%
Elevance Health logo
Elevance HealthELV
$9.66B+28.8%

Other financials

Income statement

See full
Revenue$496.2M+2.6%
Gross profit$83.8M-18.2%
Operating income-$10.6M-553%
Net income-$26.6M+58.8%
EPS (diluted)-$0.24+61.9%

Balance sheet

See full
Total debt$985.4M+13.3%
Total equity$396.4M-57.6%
Total assets$1.9B-29.2%

Cash flow

See full
Operating cash flow-$984.0K-122%

Valuation

See full
Market cap$565.78M-47.9%
Enterprise value$1.41B-17.6%
P/S0.3×-0.2×

Profitability

See full
Gross margin20.2%+4.9pp
Operating margin-22.2%-23.5pp
Net margin-26.3%-33.2pp
FCF margin-9.7%

Returns & leverage

See full
Return on equity-74.6%-90.1pp
Debt / equity2.5×+1.6×
Current ratio1.3×+0.3×

Where this comes from

Reported directly by Evolent Health, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The official record: Evolent Health, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Evolent Health, Inc.'s cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Evolent Health, Inc.'s cash & equivalents?
Evolent Health, Inc. (EVH) reported cash & equivalents of $142.03M in Q1 2026.
How has Evolent Health, Inc.'s cash & equivalents changed year-over-year?
Evolent Health, Inc.'s cash & equivalents decreased by 42.4% year-over-year, from $246.55M to $142.03M.
What is the long-term trend for Evolent Health, Inc.'s cash & equivalents?
Over 5 years (2020 to 2025), Evolent Health, Inc.'s cash & equivalents has grown at a -13.8% compound annual growth rate (CAGR), from $319M to $151.86M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.